← Eichor
Study identifier: NCT07493239 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

A Decentralized Clinical Study Evaluating the Effectiveness of Two Different Doses of MyCondro™ on Physical Mobility and Joint Health

Condition: Joint Health  ·  Sponsor: Lesaffre International

PhaseNA
Planned participants240
Who can joinAll sexes, 45 Years to no upper limit
Healthy volunteersYes

About this study

This study evaluates the effect of two different doses of a consumer-grade product, MyCondro™, on individuals experiencing mobility issues related to knee osteoarthritis. The primary goal is to measure improvements in overall joint health and mobility by tracking changes in participants' total WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) scores from the beginning to the end of the trial. Additionally, the study aims to assess secondary outcomes, including the product's impact on pain, stiffness, knee function, patient-reported improvement, inflammatory blood markers (CRP), and daily physical activity.

This description comes directly from the study's public registry record.

Talk to the study team

Victoria Oyedokun, PhD  ·  +4915163496903  ·  v.oyedokun@gnosis.lesaffre.com

Yann Fardini, PhD  ·  y.fardini@gnosis.lesaffre.com

Always discuss trial participation with your own doctor first.

Locations (1)

People ScienceLos Angeles, California, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07493239